Astrazeneca (AZN) Interest & Investment Income (2009 - 2026)

Astrazeneca's Interest & Investment Income history runs 18 years deep, the most recent figure standing at $73.0 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 13.1% year-over-year to $73.0 million; the TTM figure through Mar 2026 stood at $73.0 million (down 13.1% YoY), while the FY2025 annual figure was $135.0 million, down 70.52% from the prior year.
• Interest & Investment Income was $73.0 million for Q1 2026 at Astrazeneca, down from $135.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $236.0 million in Q3 2023 to a low of $17.0 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $113.4 million across 5 years, with a median of $98.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 372.0% in 2023, then plunged 53.55% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $50.0 million in 2022, then jumped by 372.0% to $236.0 million in 2023, then slipped by 22.46% to $183.0 million in 2024, then retreated by 26.23% to $135.0 million in 2025, then sank by 45.93% to $73.0 million in 2026.
• The last three Interest & Investment Income figures came in at $73.0 million (Q1 2026), $135.0 million (Q4 2025), and $85.0 million (Q3 2025), per Business Quant data.